| P2093 | author name string | Gang Li | |
| | Almass-Houd Aguissa-Touré | |
| P2860 | cites work | The lipid phosphatase activity of PTEN is critical for its tumor supressor function | Q22007981 |
| | The tumor suppressor PTEN is phosphorylated by the protein kinase CK2 at its C terminus. Implications for PTEN stability to proteasome-mediated degradation | Q24290417 |
| | Ubiquitination regulates PTEN nuclear import and tumor suppression | Q24292946 |
| | TEP1, encoded by a candidate tumor suppressor locus, is a novel protein tyrosine phosphatase regulated by transforming growth factor beta | Q24310394 |
| | The tumor suppressor, PTEN/MMAC1, dephosphorylates the lipid second messenger, phosphatidylinositol 3,4,5-trisphosphate | Q24317714 |
| | P-TEN, the tumor suppressor from human chromosome 10q23, is a dual-specificity phosphatase | Q24322705 |
| | Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a | Q24324559 |
| | Nuclear PTEN regulates the APC-CDH1 tumor-suppressive complex in a phosphatase-independent manner | Q24337323 |
| | Protean PTEN: form and function | Q24613810 |
| | Improved survival with vemurafenib in melanoma with BRAF V600E mutation | Q24631953 |
| | A coding-independent function of gene and pseudogene mRNAs regulates tumour biology | Q24632651 |
| | Integrated Molecular and Clinical Analysis of AKT Activation in Metastatic Melanoma | Q42723115 |
| | Disruption of the MMAC1/PTEN gene by deletion or mutation is a frequent event in malignant melanoma | Q42815905 |
| | Identification of PTEN/MMAC1 alterations in uncultured melanomas and melanoma cell lines | Q42818580 |
| | PTEN: Sometimes Taking It Off Can Be Better than Putting It On | Q43104730 |
| | High frequency of submicroscopic hemizygous deletion is a major mechanism of loss of expression of PTEN in uveal melanoma | Q43509621 |
| | Detection of new PTEN/MMAC1 mutations in head and neck squamous cell carcinomas with loss of chromosome 10. | Q43860454 |
| | Promoter methylation and silencing of PTEN in gastric carcinoma | Q43918868 |
| | Analysis of genetic and epigenetic alterations of the PTEN gene in gastric cancer | Q43966008 |
| | Phosphorylation-regulated cleavage of the tumor suppressor PTEN by caspase-3: implications for the control of protein stability and PTEN-protein interactions | Q44467149 |
| | Mutation spectrum and genotype-phenotype analyses in Cowden disease and Bannayan-Zonana syndrome, two hamartoma syndromes with germline PTEN mutation | Q45345194 |
| | Both lipid- and protein-phosphatase activities of PTEN contribute to the p53-PTEN anti-invasion pathway | Q45908947 |
| | Loss of heterozygosity for 10q22-10qter in malignant melanoma progression | Q46160835 |
| | Epithelial Pten is dispensable for intestinal homeostasis but suppresses adenoma development and progression after Apc mutation | Q46244569 |
| | Loss of the p16INK4a and p15INK4b genes, as well as neighboring 9p21 markers, in sporadic melanoma | Q46912733 |
| | BRAF alterations are associated with complex mutational profiles in malignant melanoma | Q47349130 |
| | The PTEN tumour suppressor gene and malignant melanoma. | Q48379706 |
| | Somatic mutations of PTEN in glioblastoma multiforme | Q48618632 |
| | PTEN promoter methylation in sporadic thyroid carcinomas | Q48645805 |
| | Pten deficiency in melanocytes results in resistance to hair graying and susceptibility to carcinogen-induced melanomagenesis | Q49074092 |
| | Stabilization and productive positioning roles of the C2 domain of PTEN tumor suppressor | Q49086388 |
| | PTEN mutation spectrum in breast cancers and breast hyperplasia | Q53300858 |
| | PTEN/MMAC1 mutations in endometrial cancers | Q53439663 |
| | Somatic deletions and mutations in the Cowden disease gene, PTEN, in sporadic thyroid tumors | Q53439669 |
| | Analysis of PTEN gene mutations in Korean patients with Cowden syndrome and polyposis syndrome | Q53667014 |
| | Braf(V600E) cooperates with Pten loss to induce metastatic melanoma | Q39873596 |
| | The protein phosphatase activity of PTEN regulates SRC family kinases and controls glioma migration | Q40002542 |
| | Genomic profiling of malignant melanoma using tiling-resolution arrayCGH. | Q40177784 |
| | Osteopontin is a downstream effector of the PI3-kinase pathway in melanomas that is inversely correlated with functional PTEN. | Q40298565 |
| | Regulation of cell migration by the C2 domain of the tumor suppressor PTEN. | Q40587498 |
| | Regulation of Raf-Akt Cross-talk | Q40727585 |
| | Lack of PTEN expression in non-small cell lung cancer could be related to promoter methylation | Q40732720 |
| | Cell cycle arrest by the PTEN tumor suppressor is target cell specific and may require protein phosphatase activity | Q40768754 |
| | Glial cell line-derived neurotrophic factor-stimulated phosphatidylinositol 3-kinase and Akt activities exert opposing effects on the ERK pathway: importance for the rescue of neuroectodermic cells | Q40782343 |
| | Relative reciprocity of NRAS and PTEN/MMAC1 alterations in cutaneous melanoma cell lines. | Q40887108 |
| | The phosphoinositol phosphatase activity of PTEN mediates a serum-sensitive G1 growth arrest in glioma cells | Q40993616 |
| | Deletion mapping of the long arm of chromosome 10 in glioblastoma multiforme | Q41075821 |
| | Pten controls lung morphogenesis, bronchioalveolar stem cells, and onset of lung adenocarcinomas in mice. | Q41377207 |
| | Molecular genetics of familial cutaneous melanoma | Q41704108 |
| | Pten, a protean tumor suppressor | Q42125233 |
| | Basal and treatment-induced activation of AKT mediates resistance to cell death by AZD6244 (ARRY-142886) in Braf-mutant human cutaneous melanoma cells | Q42478581 |
| | AKT/PKB signaling: navigating downstream | Q24657857 |
| | The PTEN-regulating microRNA miR-26a is amplified in high-grade glioma and facilitates gliomagenesis in vivo | Q24657924 |
| | Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis | Q24681977 |
| | Crystal structure of the PTEN tumor suppressor: implications for its phosphoinositide phosphatase activity and membrane association | Q27620298 |
| | Crystal structure of the dual specificity protein phosphatase VHR | Q27732778 |
| | Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers | Q27851426 |
| | Inhibition of Mutated, Activated BRAF in Metastatic Melanoma | Q27860458 |
| | PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer | Q27860985 |
| | PTEN: one gene, many syndromes | Q28203387 |
| | Conditional loss of PTEN leads to precocious development and neoplasia in the mammary gland | Q28217001 |
| | Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF | Q28251989 |
| | MMAC1/PTEN mutations in primary tumor specimens and tumor cell lines | Q28256046 |
| | Mutation of the PTEN tumor suppressor gene in endometrial hyperplasias | Q28274383 |
| | Ultraviolet radiation and melanoma: a systematic review and analysis of reported sequence variants | Q28287782 |
| | Germline p16INK4A mutation and protein dysfunction in a family with inherited melanoma | Q28294331 |
| | Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers | Q28306997 |
| | Pten is essential for embryonic development and tumour suppression | Q28509238 |
| | Essential role for nuclear PTEN in maintaining chromosomal integrity | Q28513781 |
| | Inactivation of platelet-derived growth factor receptor by the tumor suppressor PTEN provides a novel mechanism of action of the phosphatase | Q28567492 |
| | Mutation of Pten/Mmac1 in mice causes neoplasia in multiple organ systems | Q28586004 |
| | Prostate-specific deletion of the murine Pten tumor suppressor gene leads to metastatic prostate cancer | Q28590839 |
| | A novel positive feedback loop mediated by the docking protein Gab1 and phosphatidylinositol 3-kinase in epidermal growth factor receptor signaling | Q28609913 |
| | BRAF mutation predicts sensitivity to MEK inhibition | Q29614281 |
| | Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K | Q29614757 |
| | Distinct sets of genetic alterations in melanoma | Q29614965 |
| | Germline mutations of the PTEN gene in Cowden disease, an inherited breast and thyroid cancer syndrome | Q29615538 |
| | Pten dependence distinguishes haematopoietic stem cells from leukaemia-initiating cells | Q29616552 |
| | Evidence of ultraviolet type mutations in xeroderma pigmentosum melanomas. | Q30487052 |
| | PTEN coordinates G(1) arrest by down-regulating cyclin D1 via its protein phosphatase activity and up-regulating p27 via its lipid phosphatase activity in a breast cancer model | Q32069431 |
| | Conditional loss of uterine Pten unfailingly and rapidly induces endometrial cancer in mice | Q33667276 |
| | The multiple roles of PTEN in tumor suppression | Q33849727 |
| | Mutations of the human PTEN gene | Q33988995 |
| | Genetic analysis of Pten and Ink4a/Arf interactions in the suppression of tumorigenesis in mice | Q34009762 |
| | Incidence of the V600K mutation among melanoma patients with BRAF mutations, and potential therapeutic response to the specific BRAF inhibitor PLX4032. | Q34049618 |
| | Identification of the miR-106b~25 microRNA cluster as a proto-oncogenic PTEN-targeting intron that cooperates with its host gene MCM7 in transformation | Q34109986 |
| | PTEN expression in melanoma: relationship with patient survival, Bcl-2 expression, and proliferation | Q53850298 |
| | Prevalence of BRAF V600E mutation in Chinese melanoma patients: large scale analysis of BRAF and NRAS mutations in a 432-case cohort | Q54357561 |
| | Hyperplasia and carcinomas in Pten-deficient mice and reduced PTEN protein in human bladder cancer patients. | Q54583947 |
| | T Cell-Specific Loss of Pten Leads to Defects in Central and Peripheral Tolerance | Q57185252 |
| | Loss of heterozygosity in sporadic primary cutaneous melanoma | Q58039432 |
| | PTEN maintains haematopoietic stem cells and acts in lineage choice and leukaemia prevention | Q59067116 |
| | PTEN inactivation is rare in melanoma tumours but occurs frequently in melanoma cell lines | Q61953713 |
| | Genetics of melanoma | Q67253323 |
| | Possible involvement of the chromosome region 10q24----q26 in early stages of melanocytic neoplasia | Q68519985 |
| | Allelic loss on chromosome 10 in prostate adenocarcinoma | Q71046868 |
| | Chromosome 10 allelic loss in malignant melanoma | Q71612288 |
| | Frequency of homozygous deletion at p16/CDKN2 in primary human tumours | Q71721193 |
| | PTEN and MXI1 allelic loss on chromosome 10q is rare in melanoma in vivo | Q73158104 |
| | PTEN methylation is associated with advanced stage and microsatellite instability in endometrial carcinoma | Q73374555 |
| | Mutation and allelic loss of the PTEN/MMAC1 gene in primary and metastatic melanoma biopsies | Q73395862 |
| | Anticorresponding mutations of the KRAS and PTEN genes in human endometrial cancer | Q73681771 |
| | Mutations in PTEN are frequent in endometrial carcinoma but rare in other common gynecological malignancies | Q73722520 |
| | PTEN/MMAC1 in malignant melanoma and its importance for tumor progression | Q73739349 |
| | Allelic losses on chromosome arm 10q and mutation of the PTEN (MMAC1) tumour suppressor gene in primary and metastatic malignant melanomas | Q73957569 |
| | Interfocal heterogeneity of PTEN/MMAC1 gene alterations in multiple metastatic prostate cancer tissues | Q74093343 |
| | Suppression of tumorigenicity and metastasis in B16F10 cells by PTEN/MMAC1/TEP1 gene | Q74608375 |
| | Somatic mutations of thePTEN tumor suppressor gene in sporadic follicular thyroid tumors | Q77470719 |
| | Epigenetic silencing of the PTEN gene in melanoma | Q79834343 |
| | Promoter methylation of the PTEN gene is a common molecular change in breast cancer | Q80403566 |
| | PTEN promoter methylation and LOH of 10q22-23 locus in PTEN expression of ovarian clear cell adenocarcinomas | Q82600359 |
| | Prostate cancer in Cowden syndrome: somatic loss and germline mutation of the PTEN gene | Q84016729 |
| | Methylation of PTEN as a prognostic factor in malignant melanoma of the skin | Q84616428 |
| | PTEN expression in normal skin, acquired melanocytic nevi, and cutaneous melanoma | Q94325481 |
| | High frequency of BRAF mutations in nevi | Q34160519 |
| | Cooperative interactions of PTEN deficiency and RAS activation in melanoma metastasis | Q34338564 |
| | Hepatocyte-specific Pten deficiency results in steatohepatitis and hepatocellular carcinomas | Q34380511 |
| | From form to function: signaling by protein tyrosine phosphatases. | Q34405391 |
| | Reduction of Pten dose leads to neoplastic development in multiple organs of Pten (shRNA) mice | Q34479331 |
| | Metastatic melanoma | Q34678227 |
| | Germline mutations in the PTEN/MMAC1 gene in patients with Cowden disease. | Q34742581 |
| | PTEN loss confers BRAF inhibitor resistance to melanoma cells through the suppression of BIM expression | Q34761941 |
| | PTEN hamartoma tumor syndrome: an overview | Q34996547 |
| | Subtle variations in Pten dose determine cancer susceptibility | Q35055350 |
| | PTEN signaling pathways in melanoma | Q35146572 |
| | Cooperative effects of INK4a and ras in melanoma susceptibility in vivo | Q35195311 |
| | Identification of PTEN mutations in metastatic melanoma specimens | Q35435625 |
| | Comprehensive mutational analysis of CDKN2A and CDK4 in Greek patients with cutaneous melanoma | Q35577168 |
| | JAK/STAT, Raf/MEK/ERK, PI3K/Akt and BCR-ABL in cell cycle progression and leukemogenesis | Q35635353 |
| | Concurrent loss of the PTEN and RB1 tumor suppressors attenuates RAF dependence in melanomas harboring (V600E)BRAF | Q35700459 |
| | Epigenetic PTEN silencing in malignant melanomas without PTEN mutation | Q35745799 |
| | In vitro loss of heterozygosity targets the PTEN/MMAC1 gene in melanoma | Q36260162 |
| | Ki67 expression levels are a better marker of reduced melanoma growth following MEK inhibitor treatment than phospho-ERK levels. | Q36609858 |
| | Toward a molecular classification of melanoma. | Q36795253 |
| | Genetic interaction between NRAS and BRAF mutations and PTEN/MMAC1 inactivation in melanoma | Q36982042 |
| | New insights into PTEN. | Q37011116 |
| | Integrating BRAF/MEK inhibitors into combination therapy for melanoma. | Q37135238 |
| | PTEN and the PI3-kinase pathway in cancer | Q37259680 |
| | Genetic and phenotypic heterogeneity in the PTEN hamartoma tumour syndrome. | Q37270416 |
| | Post-translational regulation of PTEN. | Q37270440 |
| | The role of PTEN signaling perturbations in cancer and in targeted therapy | Q37270446 |
| | PTEN signaling pathways in glioblastoma | Q37287036 |
| | Faithfull modeling of PTEN loss driven diseases in the mouse | Q37765216 |
| | APC/C-Cdh1: from cell cycle to cellular differentiation and genomic integrity | Q37799221 |
| | Phosphoinositide 3-kinase is not overexpressed in melanocytic lesions | Q38433940 |
| | Somatic alterations in the melanoma genome: a high-resolution array-based comparative genomic hybridization study | Q39693657 |
| | MicroRNA-21 (miR-21) represses tumor suppressor PTEN and promotes growth and invasion in non-small cell lung cancer (NSCLC). | Q39728869 |
| | Suppression of cellular proliferation and invasion by the concerted lipid and protein phosphatase activities of PTEN. | Q39774233 |
| | Identification of direct transcriptional targets of (V600E)BRAF/MEK signalling in melanoma | Q39812581 |
| P433 | issue | 9 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | tumor suppressor gene | Q422445 |
| P304 | page(s) | 1475-1491 | |
| P577 | publication date | 2011-11-11 | |
| P1433 | published in | Cellular and Molecular Life Sciences | Q5058352 |
| P1476 | title | Genetic alterations of PTEN in human melanoma | |
| P478 | volume | 69 | |